Inhaled iloprost as part of combination therapy for persistent pulmonary hypertension of the newborn
Keywords:
Inhaled iloprost, persistent pulmonary hypertension, newborn
Abstract
Persistent pulmonary hypertension of thenewborn (PPHN) is rare, but life-threatening.
If not treated, PPHN may cause respiratory
failure and death in neonates. l,2,3 PPHN
often occurs in term or post-term infants with a history
of difficult labor, infection or asphyxia during birth.
These infants do not have adequate oxygen during
labor.3 Based on etiology, PPHN can be categorized
into primary PPHN, which occurs by itself without
apparent cause; or secondary PPHN, which is caused
by meconium aspiration, hyaline membrane disease,
neonatal sepsis with pneumonia, congenital heart
abnormality, or maternal drug use (non-steroidal
anti-inflammatories, methamphetamine, or selective
serotonin re uptake inhibitors) during the third
trimester of pregnancy.
References
1. Mok 0, Yates R, Tasker RC. Persistent pulmonary hypertension
of the term neonate: a strategy for management. Eur
J Pediatr. 1999;158:825-7.
2. Graves ED, Redmond CR, Arensman RM. Persistent
pulmonary hypertension in the neonate. Chest. 1988;93:
638-41.
3. Kohnle D. Persistent pulmonary hypertension of the
newborn (PPHN) . EBSCO, Neonatology Children's
Memorial Hospital July, 2008 [homepage on the Internet] .
c2008. [cited 2011 July 5); Av ailable from: http://
www.empowher.com/media/reference/persistent-pulmonary
hypertension-newborn.
4. University of California Medical center. Persistent pulmonary
hypertension of the newborn (PPHN). Intensive care nursery
house staff manual [homepage on the Internet]. c2006 [cited
2009 May]. Available from: http://www.ucsfhealth.org.
5. Rashid A, Ivy D. Severe paediatric pulmonary hypertension:
new management strategies. Arch Dis Child. 2005;
90:92-8.
6. Hoeper MM, Galie N, Simonneau G, Rubin LJ. New
treatments for pulmonary arterial hypertension. AmJ Respir
Crit Care Med. 2002;165:1209-16.
7. Walmrath D, Schneider T, Pilch J, Grimminger F, Seeger
W. Aerosolized prostacyclin in adult respiratory distress
syndrome. Lancet. 1993;342:961-2.
8. Zwissler B, Kemming G, Habler 0, Kleen M, Merkel M, Haller
M, et al. Inhaled prostacyclin (PGI2) versus inhaled nitric
oxide in ad ult respiratory distress syndrome. Am J Respir Crit
Care Med. 1996;154:1671-7 .
9. Olsch eski H, Gh ofrani HA, Walmrath D, Schermuly R,
Temmesfeld-Wollbruck B, Grimminger F, et al. Inhaled
prostacyclin and iloprost in severe pulmonary hypertension
secondary to lung fibrosis. Am J Respirat Crit Care Med.
1999; 160:600-7.
10. Ehlen M, Wiebe B. Iloprost in persistent pulmonary hypertension
of the newborn. Cardiel Young. 2003;13:361-3.
11. Lambert V, Serraf A, Durand P, Losay J. Aerosolized iloprost
therapy in an infant with chronic pulmonary hypertension
60 • Paediatr Indones, Vol. 52, No. 1, January 2012
after a neonatal arterial switch operation. Arch Pediatr.
2001;8: 1218-21.
12. Concheiro GA, Sousa RC, Suarez TB, Paradela CA, Ocampo
CS, Antelo DJ. Inhaled iloprost: a therapeutic alternative
for persistent pulmonary hypertension of the newborn. An
Pediatr (Bare). 2005;63:175-6.
13. Dembinski R, Brackhahn W, Henzler D, Rott A, Bensberg
R, Kuhlen R, et al. Cardiopulmonary effects of iloprost in
experimental acute lung injury. Eur Resp J. 2005;25 :81-7 .
14. Tissieres P, N icod L, Argiroffo CB, Rimensberger PC, Beghetti
M. Aerosolized iloprost as a bridge to lung transplantation
in a patient with cystic fibrosis and pulmonary hypertension.
Ann Thorac Surg. 2004;78:48-50.
15. Walmrath D, Scheneider T, Pilch], Schermuly R, Grimminger
F, Seeger W. Effects of aerosolized prostacyclin in severe
pneumonia. Impact of fibrosis. Am J Respir Crit Care Med.
1995;151:724-30.
16. Walmrath D, Schneider T, Schermuly R, Olschewski
H, Grimminger F, Seeger W. Direct comparison of
inhaled nitric oxide and aerosolized prostacyclin in acute
respiratory distress syndrome. Am J Respir Crit Care Med.
1996; 153:991-6.
17. Fitscha P, Tiso B, Krais T, Sinzinger H. Effect ofiloprost on in
vivo and in vitro platelet function in patients with peripheral
vascular disease (PVD). Adv Prostaglandin Thromboxane
Leukot Res. 1987;17A:450-4.
18. Hoeper MM, Olschewski H, Ghofrani HA, Wilkens H,
Winkler J, Borst MM, et al. A comparison of the acute
hemodynamic effects of inhaled nitric oxide and aerosolized
iloprost in primary pulmonary hypertension. J Am Coll
Cardie l. 2000;35: 176-82.
19. Gessler T, Schmehl T, Hoeper MM, Rose F, Ghofrani HA,
Olschewski H, et al. Ultrasonic versus jet nebulization of
iloprost in severe pulmonary hyper tension. Eur Respir J.
2001;17: 14-9.
20. Jaratwashirakul S. Inhaled iloprost for severe persistent
pulmonary hypertension of the n ewborn. J Med Assoc Thai.
2007;90: 167-70.
21. Mullen PM, Wessel DL. Pharmacological treatment of
pulmonary hypertension. In: Munoz R, Schmitt CG, Roth
SJ, Cruz ED, editors. Handbook of pediatric cardiovascular
drugs. London: Springer; 2008. p. 226-47.
22. Muller JC. Iloprost inhalation in early therapy of pediatric
lung failure. Journal fur Anasthesie und Intensiv behandlung.
2007;7: 150.
of the term neonate: a strategy for management. Eur
J Pediatr. 1999;158:825-7.
2. Graves ED, Redmond CR, Arensman RM. Persistent
pulmonary hypertension in the neonate. Chest. 1988;93:
638-41.
3. Kohnle D. Persistent pulmonary hypertension of the
newborn (PPHN) . EBSCO, Neonatology Children's
Memorial Hospital July, 2008 [homepage on the Internet] .
c2008. [cited 2011 July 5); Av ailable from: http://
www.empowher.com/media/reference/persistent-pulmonary
hypertension-newborn.
4. University of California Medical center. Persistent pulmonary
hypertension of the newborn (PPHN). Intensive care nursery
house staff manual [homepage on the Internet]. c2006 [cited
2009 May]. Available from: http://www.ucsfhealth.org.
5. Rashid A, Ivy D. Severe paediatric pulmonary hypertension:
new management strategies. Arch Dis Child. 2005;
90:92-8.
6. Hoeper MM, Galie N, Simonneau G, Rubin LJ. New
treatments for pulmonary arterial hypertension. AmJ Respir
Crit Care Med. 2002;165:1209-16.
7. Walmrath D, Schneider T, Pilch J, Grimminger F, Seeger
W. Aerosolized prostacyclin in adult respiratory distress
syndrome. Lancet. 1993;342:961-2.
8. Zwissler B, Kemming G, Habler 0, Kleen M, Merkel M, Haller
M, et al. Inhaled prostacyclin (PGI2) versus inhaled nitric
oxide in ad ult respiratory distress syndrome. Am J Respir Crit
Care Med. 1996;154:1671-7 .
9. Olsch eski H, Gh ofrani HA, Walmrath D, Schermuly R,
Temmesfeld-Wollbruck B, Grimminger F, et al. Inhaled
prostacyclin and iloprost in severe pulmonary hypertension
secondary to lung fibrosis. Am J Respirat Crit Care Med.
1999; 160:600-7.
10. Ehlen M, Wiebe B. Iloprost in persistent pulmonary hypertension
of the newborn. Cardiel Young. 2003;13:361-3.
11. Lambert V, Serraf A, Durand P, Losay J. Aerosolized iloprost
therapy in an infant with chronic pulmonary hypertension
60 • Paediatr Indones, Vol. 52, No. 1, January 2012
after a neonatal arterial switch operation. Arch Pediatr.
2001;8: 1218-21.
12. Concheiro GA, Sousa RC, Suarez TB, Paradela CA, Ocampo
CS, Antelo DJ. Inhaled iloprost: a therapeutic alternative
for persistent pulmonary hypertension of the newborn. An
Pediatr (Bare). 2005;63:175-6.
13. Dembinski R, Brackhahn W, Henzler D, Rott A, Bensberg
R, Kuhlen R, et al. Cardiopulmonary effects of iloprost in
experimental acute lung injury. Eur Resp J. 2005;25 :81-7 .
14. Tissieres P, N icod L, Argiroffo CB, Rimensberger PC, Beghetti
M. Aerosolized iloprost as a bridge to lung transplantation
in a patient with cystic fibrosis and pulmonary hypertension.
Ann Thorac Surg. 2004;78:48-50.
15. Walmrath D, Scheneider T, Pilch], Schermuly R, Grimminger
F, Seeger W. Effects of aerosolized prostacyclin in severe
pneumonia. Impact of fibrosis. Am J Respir Crit Care Med.
1995;151:724-30.
16. Walmrath D, Schneider T, Schermuly R, Olschewski
H, Grimminger F, Seeger W. Direct comparison of
inhaled nitric oxide and aerosolized prostacyclin in acute
respiratory distress syndrome. Am J Respir Crit Care Med.
1996; 153:991-6.
17. Fitscha P, Tiso B, Krais T, Sinzinger H. Effect ofiloprost on in
vivo and in vitro platelet function in patients with peripheral
vascular disease (PVD). Adv Prostaglandin Thromboxane
Leukot Res. 1987;17A:450-4.
18. Hoeper MM, Olschewski H, Ghofrani HA, Wilkens H,
Winkler J, Borst MM, et al. A comparison of the acute
hemodynamic effects of inhaled nitric oxide and aerosolized
iloprost in primary pulmonary hypertension. J Am Coll
Cardie l. 2000;35: 176-82.
19. Gessler T, Schmehl T, Hoeper MM, Rose F, Ghofrani HA,
Olschewski H, et al. Ultrasonic versus jet nebulization of
iloprost in severe pulmonary hyper tension. Eur Respir J.
2001;17: 14-9.
20. Jaratwashirakul S. Inhaled iloprost for severe persistent
pulmonary hypertension of the n ewborn. J Med Assoc Thai.
2007;90: 167-70.
21. Mullen PM, Wessel DL. Pharmacological treatment of
pulmonary hypertension. In: Munoz R, Schmitt CG, Roth
SJ, Cruz ED, editors. Handbook of pediatric cardiovascular
drugs. London: Springer; 2008. p. 226-47.
22. Muller JC. Iloprost inhalation in early therapy of pediatric
lung failure. Journal fur Anasthesie und Intensiv behandlung.
2007;7: 150.
Published
2012-03-30
How to Cite
1.
Samudro H, Djer M. Inhaled iloprost as part of combination therapy for persistent pulmonary hypertension of the newborn. PI [Internet]. 30Mar.2012 [cited 22Nov.2024];52(1):57-0. Available from: https://paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/319
Section
Articles
Authors who publish with this journal agree to the following terms:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
Received 2016-08-22
Accepted 2016-08-22
Published 2012-03-30
Accepted 2016-08-22
Published 2012-03-30
